skip to main content
Overview
Toggle Button Open

October 12, 2026

By: Brandon W. Shirley

On October 9, 2026, the American Hospital Association (“AHA”) and several hospital plaintiffs filed suit in the U.S. District Court for the District of Maine seeking to halt HRSA’s revised 340B Rebate Model Pilot Program before its scheduled January 1, 2027, launch (“Complaint”). The Complaint asks the court to set aside the program and enjoin HRSA from implementing approved manufacturer rebate plans, alleging that the agency failed to adequately assess the costs, burdens, and operational consequences of the program. While the litigation creates uncertainty regarding the program’s future, the rebate model remains scheduled to take effect on January 1, 2027. Unless the court issues injunctive relief, covered entities should continue preparing for implementation.

The Rebate Model at a Glance

The 340B pilot program is similar to the proposal HRSA advanced late last year. Under HRSA’s revised pilot, participating manufacturers provide 340B pricing through post-dispense rebates for selected drugs included in the Medicare Drug Price Negotiation Program. Covered entities purchase those drugs at wholesale acquisition cost (WAC), submit claims-level data through an approved platform, and receive a rebate equal to the difference between WAC and the applicable 340B ceiling price.  HRSA published its revised pilot program on August 3, 2026, with intention to launch it on January 1, 2027. The pilot applies only to selected Medicare-negotiated drugs and remains limited in scope compared to overall 340B purchases.

On October 1, 2026, HRSA approved rebate-model plans submitted by ten manufacturers covering eighteen drugs that will become subject to the pilot beginning January 1, 2027. According to HRSA, approved manufacturers include AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, and Teva. The approved drugs include several high-cost and widely utilized therapies, which can be found in HRSA’s announcement.

The Complaint

The Complaint contends that HRSA’s implementation of the revised pilot program violates the Administrative Procedure Act (“APA”). Among other claims, the plaintiffs allege that HRSA: underestimated the administrative costs associated with compliance; failed to adequately consider staffing, technology, training, reconciliation, and vendor expenses; ignored the cash-flow impact of requiring covered entities to purchase drugs at WAC and await reimbursement through rebates; failed to properly account for decades of reliance on the traditional upfront-discount model; did not meaningfully evaluate less burdensome alternatives; and relied on unsupported assumptions regarding the frequency of duplicate discounts and the benefits of a rebate-based system. The plaintiffs are seeking declaratory and injunctive relief that would prevent implementation of the program before its January 1, 2027, effective date.

The litigation should move quickly given the rebate’s program’s impact, stakeholder interest, and the January 1, 2027, start date. As such, covered entities should closely monitor litigation updates and plan accordingly. In the interim, unless and until a court issues an order delaying or enjoining implementation, covered entities should continue preparing for compliance with the rebate model’s January 1, 2027, effective date.

We will continue to monitor the litigation and any developments affecting the January 1, 2027, implementation date. For questions regarding the 340B Rebate Model Pilot Program, the pending litigation, or preparation for implementation, please contact Brandon W. Shirley.
 


Disclaimer: The contents of this article should not be construed as legal advice or a legal opinion on any specific facts or circumstances. The contents are intended for general informational purposes only, and you are urged to consult with counsel concerning your situation and specific legal questions you may have.

October 12, 2026

By: Brandon W. Shirley

On October 9, 2026, the American Hospital Association (“AHA”) and several hospital plaintiffs filed suit in the U.S. District Court for the District of Maine seeking to halt HRSA’s revised 340B Rebate Model Pilot Program before its scheduled January 1, 2027, launch (“Complaint”). The Complaint asks the court to set aside the program and enjoin HRSA from implementing approved manufacturer rebate plans, alleging that the agency failed to adequately assess the costs, burdens, and operational consequences of the program. While the litigation creates uncertainty regarding the program’s future, the rebate model remains scheduled to take effect on January 1, 2027. Unless the court issues injunctive relief, covered entities should continue preparing for implementation.

The Rebate Model at a Glance

The 340B pilot program is similar to the proposal HRSA advanced late last year. Under HRSA’s revised pilot, participating manufacturers provide 340B pricing through post-dispense rebates for selected drugs included in the Medicare Drug Price Negotiation Program. Covered entities purchase those drugs at wholesale acquisition cost (WAC), submit claims-level data through an approved platform, and receive a rebate equal to the difference between WAC and the applicable 340B ceiling price.  HRSA published its revised pilot program on August 3, 2026, with intention to launch it on January 1, 2027. The pilot applies only to selected Medicare-negotiated drugs and remains limited in scope compared to overall 340B purchases.

On October 1, 2026, HRSA approved rebate-model plans submitted by ten manufacturers covering eighteen drugs that will become subject to the pilot beginning January 1, 2027. According to HRSA, approved manufacturers include AbbVie, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Pfizer, and Teva. The approved drugs include several high-cost and widely utilized therapies, which can be found in HRSA’s announcement.

The Complaint

The Complaint contends that HRSA’s implementation of the revised pilot program violates the Administrative Procedure Act (“APA”). Among other claims, the plaintiffs allege that HRSA: underestimated the administrative costs associated with compliance; failed to adequately consider staffing, technology, training, reconciliation, and vendor expenses; ignored the cash-flow impact of requiring covered entities to purchase drugs at WAC and await reimbursement through rebates; failed to properly account for decades of reliance on the traditional upfront-discount model; did not meaningfully evaluate less burdensome alternatives; and relied on unsupported assumptions regarding the frequency of duplicate discounts and the benefits of a rebate-based system. The plaintiffs are seeking declaratory and injunctive relief that would prevent implementation of the program before its January 1, 2027, effective date.

The litigation should move quickly given the rebate’s program’s impact, stakeholder interest, and the January 1, 2027, start date. As such, covered entities should closely monitor litigation updates and plan accordingly. In the interim, unless and until a court issues an order delaying or enjoining implementation, covered entities should continue preparing for compliance with the rebate model’s January 1, 2027, effective date.

We will continue to monitor the litigation and any developments affecting the January 1, 2027, implementation date. For questions regarding the 340B Rebate Model Pilot Program, the pending litigation, or preparation for implementation, please contact Brandon W. Shirley.
 


Disclaimer: The contents of this article should not be construed as legal advice or a legal opinion on any specific facts or circumstances. The contents are intended for general informational purposes only, and you are urged to consult with counsel concerning your situation and specific legal questions you may have.

Practices

Industries